Dr. Franck brings to Cilcare an impressive and highly relevant career spanning more than 25 years, characterized by deep expertise across clinical audiology, hearing science, medical device development, rigorous clinical research, commercialization strategies, and cutting-edge biotechnology. His arrival is particularly timely as Cilcare intensifies its efforts to broaden its operational scope within North America, targeting lucrative opportunities in auditory therapeutics, specialized research services, and innovative drug-device combinations. The convergence of his diverse background with Cilcare’s specialized focus is anticipated to create substantial synergy, driving forward the company’s strategic objectives in a critical market.
A Distinguished Career in Auditory Science and Biotechnology
Dr. Franck’s professional trajectory illustrates a consistent dedication to the field of hearing health and an aptitude for leadership across various sectors. Most recently, he held the position of Chief Clinical Officer at Otolith Labs, a company at the forefront of developing groundbreaking technology aimed at addressing debilitating vestibular disorders. His tenure there provided him with invaluable insights into the intricacies of neuro-otological conditions and the development of innovative solutions beyond traditional hearing aids.
Prior to his role at Otolith Labs, Dr. Franck served as Senior Vice President of Strategic Marketing and New Product Planning at Frequency Therapeutics, a clinical-stage biotechnology company focused on regenerative medicine for hearing loss. At Frequency, his responsibilities were expansive, encompassing the formulation of clinical strategy, spearheading business development initiatives, meticulous pre-commercial planning, and cultivating robust engagement with both strategic partners and crucial investors. This experience provided him with a comprehensive understanding of the drug development lifecycle within the auditory space, from early-stage research to market preparation. Frequency Therapeutics’ approach, involving the activation of progenitor cells to restore inner ear function, placed Dr. Franck at the nexus of some of the most advanced research in hearing restoration, offering a unique perspective on the challenges and opportunities in this nascent field.
Earlier in his distinguished career, Dr. Franck served as the Director of Audiology at the esteemed Massachusetts Eye and Ear in Boston. In this significant role, he was responsible for overseeing a wide array of clinical audiology services and driving crucial research activities. During this period, he maintained direct patient care, working extensively with adults and children who utilized cochlear implants, advanced hearing aids, and emerging consumer hearing devices. His hands-on clinical experience provided him with a profound understanding of patient needs and the practical application of hearing technologies. Concurrent with his clinical and administrative duties, Dr. Franck also held a faculty appointment in otolaryngology at Harvard Medical School, contributing to the academic and research excellence of one of the world’s leading medical institutions. This dual role offered him a unique vantage point, bridging the gap between clinical practice, academic research, and the development of new treatments.
His extensive industry experience further includes leadership positions at Cochlear Limited, a global leader in implantable hearing solutions, where he served as Head of Clinical and Audiological Products and Strategy. At Cochlear, Dr. Franck was instrumental in shaping the strategic direction of product development and clinical application for devices that profoundly impact the lives of individuals with severe-to-profound hearing loss. Furthermore, he played a critical role at Bose, a renowned audio equipment manufacturer, where he contributed significantly to the development and commercialization of a dedicated business unit focused on addressing hearing loss. This experience at Bose allowed him to navigate the rapidly evolving landscape of consumer hearing health, understanding market dynamics and the pathway for bringing innovative hearing solutions to a broader audience.
Academically, Dr. Franck holds a PhD in Hearing Science from the University of Washington, a testament to his foundational scientific expertise. He further augmented his technical knowledge with a master’s degree in Biomedical Engineering from Johns Hopkins University, providing him with a strong engineering perspective on medical device development. Complementing his scientific and engineering background, he earned an MBA in Healthcare Management from the Wharton School, equipping him with the strategic business acumen essential for leadership in the highly competitive biotechnology and healthcare sectors. This robust educational foundation, combined with his unparalleled professional experience, positions him as a multifaceted leader uniquely suited to guide Cilcare’s ambitious North American agenda.
Cilcare’s Strategic Imperative: Expanding in North America
In his newly assumed position, Dr. Franck’s primary focus will be on strategically strengthening Cilcare’s market presence throughout North America. A key element of this strategy involves cultivating and developing robust partnerships centered around the company’s advanced clinical and research platforms. This initiative is critical for Cilcare, a company headquartered in Montpellier, France, to effectively penetrate and expand within the dynamic and highly influential North American market. The United States, in particular, represents the world’s largest pharmaceutical market and a global epicenter for biomedical research and innovation. Establishing a strong foothold here is not merely about market share but also about accessing unparalleled research talent, state-of-the-art facilities, and a vast network of academic and industry collaborators.
Cilcare’s core mission revolves around pioneering drugs and diagnostics to prevent and treat various hearing disorders, an area with significant unmet medical needs. The company’s operations span Europe, North America, and Asia, reflecting its global aspirations. The North American expansion is a strategic move to tap into a substantial patient population suffering from hearing loss, estimated by the World Health Organization (WHO) to affect over 1.5 billion people globally, with projections indicating a rise to 2.5 billion by 2050. In the US alone, nearly 30 million adults could benefit from hearing aids, yet only a fraction seek treatment, highlighting a significant gap that novel therapeutics and diagnostics could address.
A crucial component of Cilcare’s North American strategy, and one explicitly highlighted by Dr. Franck, is the company’s existing and deepening partnership with CBSET. CBSET, a leading preclinical contract research organization (CRO) known for its expertise in complex preclinical studies, is a vital ally for Cilcare’s research and development efforts. Dr. Franck specifically emphasized the opportunities associated with CBSET’s new, state-of-the-art facility in Waltham, Massachusetts. This expansion by CBSET is poised to significantly augment the capabilities available to Cilcare, creating new avenues for innovation, particularly in the rapidly evolving domain of drug-device combinations. The strategic co-location or close collaboration with such a robust preclinical partner provides Cilcare with critical infrastructure and specialized expertise to accelerate its pipeline.
Leadership Perspectives on a Strategic Appointment
Celia Belline, CEO and co-founder of Cilcare, articulated the profound strategic value of Dr. Franck’s appointment, emphasizing his unique blend of capabilities. "Kevin brings a rare combination of audiology and medical engineering expertise, research funding experience, and an extensive network across pharmaceutical companies, universities, and hospitals in the US," Belline stated. She further elaborated on the critical role these attributes will play: "These capabilities will be instrumental as Cilcare advances its programs at the intersection of auditory science, drug development, and clinical research." Belline’s comments underscore the multifaceted nature of Dr. Franck’s skill set, which aligns perfectly with Cilcare’s integrated approach to tackling hearing disorders through both pharmacological and technological means. His deep understanding of the US healthcare landscape, from academic research to commercialization, positions him as an invaluable asset for navigating the complex regulatory and market dynamics.
Echoing Belline’s enthusiasm, Dr. Franck himself expressed his excitement about joining the Cilcare team and the prospects ahead. "I’m very excited to join the Cilcare Team. I look forward to building new opportunities in North America and continuing to work closely with our long-standing partner CBSET," Dr. Franck remarked. He further highlighted the synergistic potential of their collaboration: "Its new Waltham facility will expand our capabilities and create new avenues for innovation, including drug-device combinations." His statement reflects a clear vision for leveraging existing partnerships and new resources to drive innovation, particularly in areas where traditional treatments have fallen short. The focus on drug-device combinations is particularly pertinent, as it represents a frontier in medical innovation where synergistic approaches can often yield superior patient outcomes compared to standalone therapies. For example, local drug delivery systems integrated with hearing devices could provide targeted treatment to the inner ear, minimizing systemic side effects and maximizing therapeutic efficacy.
Broader Impact and Implications for Auditory Science
Dr. Franck’s appointment signifies more than just a personnel change; it represents a strategic escalation in Cilcare’s pursuit of leadership in the auditory therapeutics space. The addition of his profound clinical and commercial leadership is expected to significantly bolster the company’s efforts in forging partnerships for auditory drug development, advanced diagnostics, and related research capabilities.
The market for hearing loss treatments is poised for substantial growth. While hearing aids and cochlear implants have made remarkable progress, they primarily address symptom management rather than underlying biological causes. There remains a significant unmet need for pharmacological interventions that can prevent, halt, or reverse various forms of hearing loss, including age-related presbycusis, noise-induced hearing loss, and ototoxicity. The global hearing aids market alone was valued at over $8 billion in 2023 and is projected to grow, yet only a fraction of those who could benefit from intervention actually receive it. This gap highlights the immense potential for innovative drug therapies and diagnostics.
Cilcare’s focus on auditory therapeutics places it in a burgeoning field that has seen increasing interest from major pharmaceutical companies and significant venture capital investment. Companies like Frequency Therapeutics (where Franck previously worked), Decibel Therapeutics, and Akouos (acquired by Eli Lilly) have attracted substantial funding and attention, demonstrating the viability and urgent need for new solutions in this domain. The advancement of gene therapies, cell regeneration techniques, and neuroprotective agents for the inner ear represents a paradigm shift, moving beyond amplification to biological restoration.
The emphasis on drug-device combinations, as highlighted by Dr. Franck, is particularly insightful. This approach recognizes that for complex sensory organs like the inner ear, a multimodal strategy may be most effective. Combining a therapeutic agent (a drug) with a delivery system (a device) can ensure precise, localized drug delivery, overcoming challenges associated with systemic administration and the delicate physiology of the inner ear. This could involve implantable devices that slowly release drugs, or even smart hearing aids that monitor inner ear health and administer treatments as needed. Such innovations hold the promise of more effective, personalized, and less invasive treatments for patients.
Furthermore, Dr. Franck’s extensive network across US pharmaceutical companies, universities, and hospitals will be invaluable. These connections are critical for facilitating collaborative research, securing clinical trial sites, engaging key opinion leaders, and navigating the intricate regulatory landscape of the FDA. His experience with research funding and business development will also be instrumental in attracting further investment and forming strategic alliances that can accelerate Cilcare’s pipeline from preclinical stages through to clinical development and potential commercialization.
Economically, this expansion signifies potential job creation in the biotechnology sector within the US, particularly in regions like Washington D.C. and Massachusetts, which are major biotech hubs. It also represents a significant foreign direct investment by Cilcare into the North American market, contributing to the vibrant innovation ecosystem. Ultimately, the successful development and commercialization of Cilcare’s auditory therapeutics and diagnostics under Dr. Franck’s leadership have the potential to profoundly improve the quality of life for millions of individuals suffering from hearing disorders, offering hope beyond current symptomatic management. This strategic move positions Cilcare to be a significant player in defining the future of hearing healthcare.
